Jiang Ying, Tan Hui Ching, Tam Wilson Wai San, Lim Toon Wei, Wang Wenru
Alice Lee Centre for Nursing Studies, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Department of Nursing, National University Hospital, Singapore.
Oncotarget. 2017 Dec 30;9(5):6586-6594. doi: 10.18632/oncotarget.23783. eCollection 2018 Jan 19.
Previous studies had suggested that Omega-3 fatty acids have pleiotropic effects and favourable safety profile, which may potentially increase the efficacy of antiarrhythmic drugs in suppressing atrial arrhythmias through combination therapy. This meta-analysis aimed to determine the effectiveness of using Omega-3 polyunsaturated fatty acids as a sole anti-arrhythmic agent or as an adjunct to existing pharmacological therapies in preventing atrial fibrillation recurrence. Randomized controlled trials published in English, from inception to December 2016, were considered. We searched for published studies in the following electronic databases: Cochrane Central Register of Controlled Trials, PubMed, EMBASE, Medline, Scopus, and Cumulative Index to Nursing and Allied Health Literature. Pooled hazard ratio (HR) and corresponding 95% confidence intervals (CI) for time to first atrial fibrillation recurrence was analysed using a fixed effects model. Four RCTs with 1,268 participants were included in the review. Our results showed that Omega-3 polyunsaturated fatty acid therapy had no effect on preventing atrial fibrillation recurrence compared to control/placebo group (HR: 1.13, 95% CI: 0.96 to 1.33, 0.14), with no significant heterogeneity found among those studies ( value = 0.15, 9 = 0.99, I = 0%). Therefore, current evidence does not support treatment benefit of Omega-3 fatty acids in preventing atrial fibrillation recurrence among patients who have not been treated by any conventional reversion treatment, or who have only been treated with pharmacological therapy.
先前的研究表明，ω-3脂肪酸具有多效性且安全性良好，通过联合治疗可能会提高抗心律失常药物抑制房性心律失常的疗效。这项荟萃分析旨在确定使用ω-3多不饱和脂肪酸作为单一抗心律失常药物或作为现有药物治疗的辅助手段预防房颤复发的有效性。纳入了从开始到2016年12月以英文发表的随机对照试验。我们在以下电子数据库中检索已发表的研究：Cochrane对照试验中央注册库、PubMed、EMBASE、Medline、Scopus以及护理与健康照护领域累积索引。使用固定效应模型分析首次房颤复发时间的合并风险比（HR）及相应的95%置信区间（CI）。该综述纳入了4项随机对照试验，共1268名参与者。我们的结果显示，与对照组/安慰剂组相比，ω-3多不饱和脂肪酸治疗对预防房颤复发无效果（HR：1.13，95%CI：0.96至1.33，P = 0.14），这些研究之间未发现显著异质性（P值 = 0.15，I² = 0.99，I = 0%）。因此，目前的证据不支持ω-3脂肪酸对未接受任何传统复律治疗或仅接受药物治疗的患者预防房颤复发有治疗益处。
